Search

Your search keyword '"Fukasawa, Satoshi"' showing total 243 results
Start Over Author "Fukasawa, Satoshi"
243 results on '"Fukasawa, Satoshi"'

1. Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial

Author

Bastick, Patricia, Sewak, Sanjeev, Tran, Ben, Pichler, Martin, Shariat, Shahrokh, Rottey, Sylvie, Schatteman, Peter, Schrijvers, Dirk, Verschaeve, Vincent, Vulsteke, Christof, Barros Leite Ferreira, Luiza Aleixo, de Santana Gomes Andrea Juliana, Pereira, Junior, Joao Antonio, Azevedo, Sergio, Bastos, Diogo, Borges, Giuliano, Dettino, Aldo, Antonio, Pires Luis, Luz, Murilo, Martins, Suelen, Mota, Jose Mauricio, Toledo, Joseane, Eigl, Bernhard, Finch, Daygen, Gingerich, Joel, Dong, Haiying, Huang, Jian, Jin, Jie, Pan, Hongming, Sun, Zhongquan, Tian, Ye, Wan, Ben, Wu, Bin, Xu, Ting, Xue, Wei, Zhou, Fangjian, Barthelemy, Philippe, Borchiellini, Delphine, Calcagno, Fabien, Carnot, Aurelien, Cornillon, Pierre, Delva, Remy, Emambux, Sheik, Houede, Nadine, Laguerre, Brigitte, Lauridant, Géraldine, Loriot, Yohann, Mahammedi, Hakim, Maillet, Denis, Pouessel, Damien, Roubaud, Guilhem, Schlurmann-Constans, Friederike, Tosi, Diego, Zanetta, Sylvie, Banek, Severine, Feyerabend, Susan, Kramer, Mario, Niegisch, Guenther, Nuhn, Philipp, Schnabel, Marco, Wuelfing, Christian, Baka, Sofia, Bamias, Aristotelis, Fountzilas, George, Kalofonos, Harabolos, Karalis, Konstantinos, Kotsakis, Athanasios, Timotheadou, Eleni, Landherr, Laszlo, Mangel, Laszlo, Pe’er, Avivit, Levratovsky, Meital, Basso, Umberto, Battelli, Nicola, Cavo, Alessia, De Giorgi, Ugo, Doni, Laura, Galli, Luca, Gigante, Maria Olga, Guadalupi, Valentina, Maio, Michele, Milesi, Laura, Nolè, Franco, Scagliotti, Giorgio, Tortora, Giampaolo, Fukasawa, Satoshi, Harabayashi, Toru, Kamiya, Naoto, Kawahara, Takashi, Kawakita, Mutsushi, Matsubara, Nobunaki, Matsumoto, Kazumasa, Nishimura, Kazuo, Rikiya, Taoka, Shimizu, Nobuaki, Tagaki, Toshio, Kang, Taek Won, Kim, Jwa Hoon, Kim, SeHyun, Lee, Hyo Jin, Lee, Yun-Gyoo, Rha, Sun Young, Seo, Ho Kyung, Los, Maartje, Zurawski, Bogdan, Cortes, Paulo, Faustino, Catia, Vau, Nuno Sineiro, da Luz, Ricardo, Atduev, Vagif, Kirtbaya, Dmitry, Kopyltsov, Evgeny, Lykov, Aleksandr, Marat, Urmantsev, Orlov, Sergey, Penkov, Konstantin, Pirmagomedov, Albert, Semenov, Andrey, Varlamov, Sergey, Anguera, Georgia, Domenech, Montserrat, Girones, Regina, Gonzalez del Alba, Aranzazu, Milagro, Nuria Lainez, Luque, Raquel, Ortega, Esther Martínez, Mellado, Begoña, Méndez Vidal, María Jose, Fernandez, Esteban Nogales, Valderrama, Begoña Perez, Marín, Alvaro Pinto, Santander, Carmen, Huang, Yi-Hsiu, Su, Wen-Pin, Wu, Hung-Chan, Wu, WenJeng, Yu, Kai-Jie, Bilici, Ahmet, Goker, Erdem, Gumus, Mahmut, Karaoglu, Aziz, Kefeli, Umut, Köse, Fatih, Ozguroglu, Mustafa, Tural, Deniz, Turk, Haci, Yalcin, Suayib, Bondarenko, Igor, Khareba, Gennadii, Kidik, Yana, Lychkovskyy, Oleksandr, Sakalo, Valerii, Shevnia, Serghii, Stakhovskyy, Eduard, Bahl, Amit, Crabb, Simon, Powles, Thomas, Sankey, Peter, Sarwar, Mohammad, Benedetto, Pasquale, Burgess, Earle, Dawson, Nancy, Doshi, Gurjyot, Fleming, Mark, Maly, Joseph, Parikh, Mamta, Waterhouse, David, Siefker-Radtke, A.O., Matsubara, N., Park, S.H., Huddart, R.A., Burgess, E.F., Özgüroğlu, M., Valderrama, B.P., Laguerre, B., Basso, U., Triantos, S., Akapame, S., Kean, Y., Deprince, K., Mukhopadhyay, S., and Loriot, Y.

Published
2024
Full Text
View/download PDF

2. Supplementary Tables S1-S5 from TAS0313 plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor—Naïve Locally Advanced or Metastatic Urothelial Carcinoma

Author

Nishiyama, Hiroyuki, primary, Yonese, Junji, primary, Kawahara, Takashi, primary, Matsumoto, Ryuji, primary, Miyake, Hideaki, primary, Matsubara, Nobuaki, primary, Uemura, Hiroji, primary, Eto, Masatoshi, primary, Azuma, Haruhito, primary, Obara, Wataru, primary, Terai, Akito, primary, Fukasawa, Satoshi, primary, and Suekane, Shigetaka, primary

Published
2024
Full Text
View/download PDF

3. Data from TAS0313 plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor—Naïve Locally Advanced or Metastatic Urothelial Carcinoma

Author

Nishiyama, Hiroyuki, primary, Yonese, Junji, primary, Kawahara, Takashi, primary, Matsumoto, Ryuji, primary, Miyake, Hideaki, primary, Matsubara, Nobuaki, primary, Uemura, Hiroji, primary, Eto, Masatoshi, primary, Azuma, Haruhito, primary, Obara, Wataru, primary, Terai, Akito, primary, Fukasawa, Satoshi, primary, and Suekane, Shigetaka, primary

Published
2024
Full Text
View/download PDF

4. Supplementary Legends from TAS0313 plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor—Naïve Locally Advanced or Metastatic Urothelial Carcinoma

Author

Nishiyama, Hiroyuki, primary, Yonese, Junji, primary, Kawahara, Takashi, primary, Matsumoto, Ryuji, primary, Miyake, Hideaki, primary, Matsubara, Nobuaki, primary, Uemura, Hiroji, primary, Eto, Masatoshi, primary, Azuma, Haruhito, primary, Obara, Wataru, primary, Terai, Akito, primary, Fukasawa, Satoshi, primary, and Suekane, Shigetaka, primary

Published
2024
Full Text
View/download PDF

5. Supplementary Figure S1 from TAS0313 plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor—Naïve Locally Advanced or Metastatic Urothelial Carcinoma

Author

Nishiyama, Hiroyuki, primary, Yonese, Junji, primary, Kawahara, Takashi, primary, Matsumoto, Ryuji, primary, Miyake, Hideaki, primary, Matsubara, Nobuaki, primary, Uemura, Hiroji, primary, Eto, Masatoshi, primary, Azuma, Haruhito, primary, Obara, Wataru, primary, Terai, Akito, primary, Fukasawa, Satoshi, primary, and Suekane, Shigetaka, primary

Published
2024
Full Text
View/download PDF

6. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Author

Cascallar, Diana Vera, Varela, Mirta, Lazzaro, Mauricio Fernandez, Kaen, Diego Lucas, Gatica, Gabriela, Flores, David Hugo, Falco, Agustin, Molina, Matias, Van Aelst, Filip, Vulsteke, Christof, Sautois, Brieuc, Machiels, Jean-Pascal, Schallier, Denis, Brust, Leandro, Rapatoni, Liane, Azevedo, Sergio J, Marinho, Gisele, Soares, Joao Paulo Holanda, Dzik, Carlos, Almeida Silva, Jamile, Fay, Andre Poisl, Gingerich, Joel, Fradet, Yves, Ferrario, Cristiano, Potvin, Kylea, Vanhuyse, Marie, Abdelsalam, Mahmoud, Cheng, Susanna, Caglevic, Christian, Reyes, Felipe, Leal, Jose Luis, Francisco, Francisco, Ibanez, Carolina, Joly, Florence, Laguerre, Brigitte, Ladoire, Sylvain, Flechon, Aude, Topart, Delphine, Huillard, Olivier, Oudard, Stéphane, Gross-Goupil, Marine, Culine, Stephane, Loriot, Yohann, Gravis, Gwenaelle, Reichardt, Peter, Retz, Margitta, Herden, Jan, Pfister, David, Ohlman, Carsten, Stoeckle, Michael, Wirth, Manfred, Lorch, Anja, Niegisch, Guenter, Goebell, Peter J, Boegemann, Martin, Merseburger, Axel, Gakis, Georgios, Bedke, Jens, Neisius, Andreas, Thomas, Christian, Hoefner, Thomas, Telekes, Andras, Kosa, Judit Erzsebet, Revesz, Janos, Bodoky, Gyorgy, Csoszi, Tibor, Csejtei, Andras, Geczi, Lajos, Ruzsa, Agnes, Kolonics, Zsuzsanna, Erfan, Jozsef, McDermott, Ray, Bambury, Richard, Sella, Avishay, Frank, Stephen Jay, Kejzman, Daniel, Goldman, Olesya, Rosenbaum, Eli, Peer, Avivit, Berger, Raanan, Rouvinov, Keren, Sarid, David, Fukasawa, Satoshi, Arai, Gaku, Yamaguchi, Akito, Yokomizo, Akira, Takayama, Tatsuya, Kinoshita, Hidefumi, Kikuchi, Eiji, Mizuno, Ryuichi, Fujii, Yasuhisa, Sassa, Naoto, Matsukawa, Yoshihisa, Fujimoto, Kiyohide, Matsubara, Nobuaki, Tanikawa, Toshiki, Tomita, Yoshihiko, Nishimura, Kazuo, Tsujihata, Masao, Oyama, Masafumi, Masumori, Naoya, Kanayama, Hiroomi, Takano, Toshimi, Miura, Yuji, Miyazaki, Jun, Joraku, Akira, Kimura, Tomokazu, Yamamoto, Yoshiaki, Kobayashi, Kazuki, De Wit, Ronald, Aarts, Maureen, Gerritsen, Winald, Los, Maartje, Beerepoot, Laurens, Izmailov, Adel, Gorelov, Sergey Igorevich, Alekseev, Boris Yakovlevich, Semenov, Andrey, Kostorov, Vladimir Anatolyevich, Alekseev, Sergey M, Zyryanov, Alexander, Oschepkov, Vasiliy Nikolaevich, Shidin, Vladimir Aleksandrovich, Vladimirov, Vladimir Ivanovich, Gafanov, Rustem Airatovich, Karlov, Petr Alexandrovich, Anderson, David Brian, Shepherd, Lucinda, Cohen, Graham Lawrence, Rapoport, Bernardo Louis, Ruff, Paul, Lee, Nari, Bae, Woo Kyun, Lee, Hyo Jin, Herranz, Urbano Anido, Rodriguez-Vida, Alejo, Morales Barrera, Rafael, Grande, Enrique, Alonso Gordoa, Teresa, Guma Padro, Josep, Gauna, Daniel Castellano, Arranz, Jose Angel, Munoz Langa, Jose, Sarrio, Regina Girones, Montesa Pino, Alvaro, Juan Fita, Maria Jose, Su, Yu-Li, Lin, Yung-Chang, Su, Wen-Pin, Shen, Ying-Chun, Chang, Yen-Hwa, Huang, Yi-Hsiu, Sriuranpong, Virote, Chansriwong, Phichai, Srimuninnimit, Vichien, Danchaivijitr, Pongwut, Abali, Huseyin, Yavuz, Sinan, Ozyilkan, Ozgur, Sendur, Mehmet Ali Nahit, Ekenel, Meltem, Ozguroglu, Mustafa, Arslan, Cagatay, Gunduz, Seyda, Ozdogan, Mustafa, Birtle, Alison, Powles, Thomas, Huddart, Robert, de Santis, Maria, Zarkar, Anjali, Evans, Linda, Hussain, Syed, DiSimone, Christopher, Muina, Antonio F, Schlegel, Peter, Jhangiani, Haresh S, Harrison, Michael, Slater, Dennis E, Wright, David, Percent, Ivor J, Lin, Jianqing, Hwang, Clara, Mamtani, Ronac, Gupta, Sumati, Bajaj, Madhuri, Galamaga, Robert, Eklund, John, Wallace, James, Shtivelband, Mikhail, Suh, Jason Jung-Gon, Burhani, Nafisa, Eadens, Matthew, Gunturu, Krishna, Burgess, Earle, Wong, John, Chaudhry, Arvind, Van Veldhuizen, Peter, Graff, Stephanie, Thomas, Christian A, Schnadig, Ian D, Carneiro, Benedito, Hussain, Maha, Morgans, Alicia, Fitzharris, John T, Oliff, Ira A, Vuky, Jacqueline, Hauke, Ralph, Baron, Ari, Joshi, Monika, Bolemon, Britt H, Jiang, Peter, Mega, Anthony E, Markus, Maurice, Pfanzelter, Nicklas, Lawler, William Eyre, Cobb, Patrick Wayne, Courtright, Jay G, Jain, Sharad, Doshi, Gurjyot, Gunuganti, Vijay K, Sartor, Oliver Alton, Cole, Scott W, Babiker, Hani, Uchio, Edward M, Drakaki, Alexandra, Mannuel, Heather D, Alva, Ajjai, Guancial, Elizabeth, Fung, Chunkit, Charles, Anthony, Amato, Robert J, Arriaga, Yull, Bowman, Isaac, Ades, Steven, Dreicer, Robert, Yu, Evan, Quinn, David I, Fleming, Mark, Csőszi, Tibor, Özgüroğlu, Mustafa, Géczi, Lajos, Cheng, Susanna Y-S, Oudard, Stephane, Fléchon, Aude, Yu, Evan Y, Nam, Kijoeng, Imai, Kentaro, and Homet Moreno, Blanca

Published
2021
Full Text
View/download PDF

7. Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial

Author

Uemura, Hiroji, Matsushima, Hisashi, Kobayashi, Kazuki, Mizusawa, Hiroya, Nishimatsu, Hiroaki, Fizazi, Karim, Smith, Matthew, Shore, Neal, Tammela, Teuvo, Tabata, Ken-ichi, Matsubara, Nobuaki, Iinuma, Masahiro, Uemura, Hirotsugu, Oya, Mototsugu, Momma, Tetsuo, Kawakita, Mutsushi, Fukasawa, Satoshi, Kobayashi, Tadahiro, Kuss, Iris, Le Berre, Marie-Aude, Snapir, Amir, Sarapohja, Toni, and Suzuki, Kazuhiro

Published
2021
Full Text
View/download PDF

8. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

Author

Wong, Suet-Lai Shirley, Tan, Thean Hsiang, Hovey, Elizabeth Jane, Clay, Timothy Dudley, Wan Ng, Siobhan Su, Rutten, Annemie, Machiels, Jean-Pascal, Dumez, Herlinde, Cheng, Susanna Yee-Shan, Ferrario, Cristiano, Sengeloev, Lisa, Jensen, Niels Viggo, Thibault, Constance, Laguerre, Brigitte, Joly, Florence, Culine, Stéphane, Becht, Catherine, Niegisch, Günter, Stöckle, Michael, Grimm, Marc-Oliver, Schwentner, Christina A, Schultze-Seemann, Wolfgang, Kalofonos, Haralambos, Mavroudis, Dimitrios, Papandreou, Christos, Karavasilis, Vasilis, Révész, Janos, Rosenbaum, Eli, Leibowitz-Amit, Raya, Kejzman, Daniel, Sarid, David, Scagliotti, Giorgio Vittorio, Bracarda, Sergio, Massari, Francesco, Osawa, Takahiro, Miyajima, Naoto, Shinohara, Nobuo, Fukuta, Fumimasa, Ohyama, Chikara, Obara, Wataru, Yamashita, Shinichi, Tomita, Yoshihiko, Kawai, Koji, Fukasawa, Satoshi, Oyama, Masafumi, Yonese, Junji, Nagata, Masayoshi, Uemura, Motohide, Nishimura, Kazuo, Kawakita, Mutsushi, Tsunemori, Hiroyuki, Hashine, Katsuyoshi, Inokuchi, Junichi, Yokomizo, Akira, Nagamori, Satoshi, Lee, Hyo Jin, Park, Se Hoon, Rha, Sun Young, Kim, Yu Jung, Lee, Yun-Gyoo, Vazquez Cortés, Leticia, Lorena Urzua Flores, Claudia, Blaisse, Reinoud J.B., Erdkamp, Fransiscus L.G., Aarts, Maureen J.B., Wojcik-Tomaszewska, Joanna, Tomczak, Piotr, Sikora-Kupis, Bozena, Schenker, Michael, Herzal, Alina Amalia, Udrea, Anghel Adrian, Karlov, Petr, Fomkin, Roman, Gajate Borau, Pablo, Grande, Enrique, Delgado Mignorance, Juan Ignacio, Su, Yu-Li, Li, Jian-Ri, Lin, Chien-Liang, Lin, Chia-Chi, Yeh, Su-Peng, Erman, Mustafa, Urun, Yuksel, Golovko, Yuriy, Bondarenko, Igor, Sinielnikov, Ivan, Crabb, Simon J., Syndikus, Isabel, Huddart, Robert, Sundar, Santhanam, Chowdhury, Simon, Sarwar, Naveed, Flaig, Thomas W., Pan, Chong Xian, Schwarz, James K., Cultrera, Jennifer Lyn, Acs, Peter Istvan, Hainsworth, John D., Herms, Benjamin T., Lawler, William Eyre, Lowe, Thomas Eugene, Petrylak, Daniel P, de Wit, Ronald, Chi, Kim N, Drakaki, Alexandra, Sternberg, Cora N, Nishiyama, Hiroyuki, Castellano, Daniel, Hussain, Syed A, Fléchon, Aude, Bamias, Aristotelis, Yu, Evan Y, van der Heijden, Michiel S, Matsubara, Nobuaki, Alekseev, Boris, Necchi, Andrea, Géczi, Lajos, Ou, Yen-Chuan, Coskun, Hasan Senol, Su, Wen-Pin, Bedke, Jens, Gakis, Georgios, Percent, Ivor J, Lee, Jae-Lyun, Tucci, Marcello, Semenov, Andrey, Laestadius, Fredrik, Peer, Avivit, Tortora, Giampaolo, Safina, Sufia, Garcia del Muro, Xavier, Rodriguez-Vida, Alejo, Cicin, Irfan, Harputluoglu, Hakan, Tagawa, Scott T, Vaishampayan, Ulka, Aragon-Ching, Jeanny B, Hamid, Oday, Liepa, Astra M, Wijayawardana, Sameera, Russo, Francesca, Walgren, Richard A, Zimmermann, Annamaria H, Hozak, Rebecca R, Bell-McGuinn, Katherine M, and Powles, Thomas

Published
2020
Full Text
View/download PDF

9. TAS0313 plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor—Naïve Locally Advanced or Metastatic Urothelial Carcinoma

Author

Nishiyama, Hiroyuki, primary, Yonese, Junji, additional, Kawahara, Takashi, additional, Matsumoto, Ryuji, additional, Miyake, Hideaki, additional, Matsubara, Nobuaki, additional, Uemura, Hiroji, additional, Eto, Masatoshi, additional, Azuma, Haruhito, additional, Obara, Wataru, additional, Terai, Akito, additional, Fukasawa, Satoshi, additional, and Suekane, Shigetaka, additional

Published
2023
Full Text
View/download PDF

10. A multicenter retrospective study of nivolumab monotherapy in previously treated metastatic renal cell carcinoma patients: interim analysis of Japanese real-world data

Author

Hinata, Nobuyuki, Yonese, Junji, Masui, Satoru, Nakai, Yasutomo, Shirotake, Suguru, Tatsugami, Katsunori, Inamoto, Teruo, Nozawa, Masahiro, Ueda, Kosuke, Etsunaga, Toru, Osawa, Takahiro, Uemura, Motohide, Kimura, Go, Numakura, Kazuyuki, Yamana, Kazutoshi, Miyake, Hideaki, Fukasawa, Satoshi, Ochi, Kenya, Kaneko, Hirokazu, and Uemura, Hirotsugu

Published
2020
Full Text
View/download PDF

14. Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases

Author

Uemura, Hirotsugu, Uemura, Hiroji, Nagamori, Satsohi, Wakumoto, Yoshiaki, Kimura, Go, Kikukawa, Hiroaki, Yokomizo, Akira, Mizokami, Atsushi, Kosaka, Takeo, Masumori, Naoya, Kawasaki, Yoshihide, Yonese, Junji, Nasu, Yasutomo, Fukasawa, Satoshi, Sugiyama, Takayuki, Kinuya, Seigo, Hosono, Makoto, Yamaguchi, Iku, Akagawa, Takashi, and Matsubara, Nobuaki

Published
2019
Full Text
View/download PDF

15. Comparison of Sequential Treatment With Androgen Receptor-Targeted Agent Followed by Another Androgen Receptor-Targeted Agent Versus Androgen Receptor-Targeted Agent Followed by Docetaxel in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer

Author

Matsubara, Nobuaki, Yamada, Yoko, Tabata, Ken-ichi, Satoh, Takefumi, Kamiya, Naoto, Suzuki, Hiroyoshi, Kawahara, Takashi, Uemura, Hiroji, Yano, Akihiro, Kawakami, Satoru, Otsuka, Masafumi, and Fukasawa, Satoshi

Published
2017
Full Text
View/download PDF

16. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

Author

Wong, Suet-Lai Shirley, Tan, Thean Hsiang, Hovey, Elizabeth Jane, Clay, Timothy Dudley, Ng, Siobhan Su Wan, Rutten, Annemie, Machiels, Jean-Pascal, Dumez, Herlinde, Cheng, Susanna Yee-Shan, Chi, Kim Nguyen, Ferrario, Cristiano, Sengeloev, Lisa, Jensen, Niels Viggo, Thibault, Constance, Laguerre, Brigitte, Laestadius, Fredrik, Joly, Florence, Flechon, Aude, Culine, Stéphane, Becht, Catherine, Niegisch, Günter, Stöckle, Michael, Grimm, Marc-Oliver, Gakis, Georgios, Schultze-Seemann, Wolfgang, Kalofonos, Haralambos, Mavroudis, Dimitrios, Papandreou, Christos, Karavasilis, Vasilis, Bamias, Aristotelis, Révész, Janos, Geczi, Lajos, Rosenbaum, Eli, Leibowitz-Amit, Raya, Kejzman, Daniel, Peer, Avivit, Sarid, David, Scagliotti, Giorgio Vittorio, Sternberg, Cora N, Tortora, Giampaolo, Bracarda, Sergio, Necchi, Andrea, Massari, Francesco, Osawa, Takahiro, Miyajima, Naoto, Shinohara, Nobuo, Fukuta, Fumimasa, Ohyama, Chikara, Obara, Wataru, Yamashita, Shinichi, Tomita, Yoshihiko, Kawai, Koji, Fukasawa, Satoshi, Matsubara, Nobuaki, Oyama, Masafumi, Yonese, Junji, Nagata, Masayoshi, Uemura, Motohide, Nishimura, Kazuo, Kawakita, Mutsushi, Tsunemori, Hiroyuki, Hashine, Katsuyoshi, Inokuchi, Junichi, Yokomizo, Akira, Nagamori, Satoshi, Lee, Jae-Lyun, Lee, Hyo Jin, Park, Se Hoon, Rha, Sun Young, Kim, Yu Jung, Lee, Yun-Gyoo, Cortés, Leticia Vazquez, Flores, Claudia Lorena Urzua, Blaisse, Reinoud J B, van der Heijden, Michiel S, de Wit, Ronald, Erdkamp, Fransiscus L G, Aarts, Maureen J B, Wojcik-Tomaszewska, Joanna, Tomczak, Piotr, Sikora-Kupis, Bozena, Schenker, Michael, Herzal, Alina Amalia, Udrea, Anghel Adrian, Karlov, Petr, Safina, Sufia Z, Alekseev, Boris, Semenov, Andrey, Fomkin, Roman, Pulido, Enrique Grande, Del Muro, F Xavier García, Mignorance, Juan Ignacio Delgado, Gauna, Daniel Castellano, Rodríguez-Vida, Alejo, Su, Yu-Li, Ou, Yen-Chuan, Lin, Chien-Liang, Su, Wen-Pin, Lin, Chia-Chi, Yeh, Su-Peng, Çiçin, Irfan, Harputluoglu, Hakan, Erman, Mustafa, Coskun, Hasan Senol, Urun, Yuksel, Golovko, Yurii, Bondarenko, Igor, Sinielnikov, Ivan, Powles, Thomas, Crabb, Simon, Syndikus, Isabel, Huddart, Robert, Sundar, Santhanam, Chowdhury, Simon, Sarwar, Naveed, Drakaki, Alexandra, Flaig, Thomas, Pan, Chong Xian, Petrylak, Daniel, Schwarz, James, Percent, Ivor, Cultrera, Jennifer, Hainsworth, John, Herms, Benjamin, Lawler, William, Lowe, Thomas, Tagawa, Scott, Aragon-Ching, Jeanny, Vaishampayan, Ulka, Petrylak, Daniel P, Chi, Kim N, Nishiyama, Hiroyuki, Castellano, Daniel, Hussain, Syed, Fléchon, Aude, Yu, Evan Y, Géczi, Lajos, Hegemann, Miriam, Percent, Ivor J, Tucci, Marcello, Safina, Sufia, del Muro, Xavier Garcia, Rodriguez-Vida, Alejo, Cicin, Irfan, Widau, Ryan C, Liepa, Astra M, Walgren, Richard A, Hamid, Oday, Zimmermann, Annamaria H, and Bell-McGuinn, Katherine M

Published
2017
Full Text
View/download PDF

17. Real‐world effectiveness of nivolumab and subsequent therapy in Japanese patients with metastatic renal cell carcinoma (POST‐NIVO study): 36‐month follow‐up results of a clinical chart review

Author

Yonese, Junji, primary, Hinata, Nobuyuki, additional, Masui, Satoru, additional, Nakai, Yasutomo, additional, Shirotake, Suguru, additional, Takeuchi, Ario, additional, Inamoto, Teruo, additional, Nozawa, Masahiro, additional, Ueda, Kosuke, additional, Etsunaga, Toru, additional, Osawa, Takahiro, additional, Uemura, Motohide, additional, Kimura, Go, additional, Numakura, Kazuyuki, additional, Yamana, Kazutoshi, additional, Miyake, Hideaki, additional, Fukasawa, Satoshi, additional, Morishima, Naoto, additional, Ito, Hiroaki, additional, and Uemura, Hirotsugu, additional

Published
2023
Full Text
View/download PDF

18. Development and validation of novel nomogram to identify the candidates for extended pelvic lymph node dissection for prostate cancer patients in the robotic era

Author

Goto, Yusuke, primary, Utsumi, Takanobu, additional, Maruo, Masafumi, additional, Kurozumi, Akira, additional, Noro, Takahide, additional, Tanaka, Satoki, additional, Sugawara, Sho, additional, Chiba, Kazuto, additional, Miyazaki, Kanetaka, additional, Inoue, Atsushi, additional, Komaru, Atsushi, additional, Fukasawa, Satoshi, additional, Imamura, Yusuke, additional, Sakamoto, Shinichi, additional, Nakatsu, Hiroomi, additional, Suzuki, Hiroyoshi, additional, Ichikawa, Tomohiko, additional, and Nagata, Maki, additional

Published
2023
Full Text
View/download PDF

19. Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study

Author

Graff, Julie N., Hoimes, Christopher J., Gerritsen, Winald R., Vaishampayan, Ulka N., Elliott, Tony, Hwang, Clara, ten Tije, Albert J., Omlin, Aurelius, McDermott, Raymond S., Fradet, Yves, Tagawa, Scott T., Kilari, Deepak, Ferrario, Cristiano, Uemura, Hiroji, Jones, Robert J., Fukasawa, Satoshi, Peer, Avivit, Niu, Cuizhen, Poehlein, Christian H., Qiu, Ping, Suttner, Leah, de Wit, Ronald, Schloss, Charles, de Bono, Johann S., and Antonarakis, Emmanuel S.

Abstract

Background: KEYNOTE-199 (NCT02787005) is a multicohort phase 2 study evaluating pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC). Results from cohorts 4 (C4) and 5 (C5) are presented. Methods: Eligible patients had not received chemotherapy for mCRPC and had responded to enzalutamide prior to developing resistance as defined by Prostate Cancer Clinical Trials Working Group 3 guidelines. Patients with RECIST-measurable disease were enrolled in C4, and patients with bone-only or bone-predominant disease were enrolled in C5. All patients received pembrolizumab 200 mg every 3 weeks for ≤35 cycles with ongoing enzalutamide until progression, unacceptable toxicity, or withdrawal. The primary end point was objective response rate (ORR) per RECIST v1.1 by blinded independent central review in C4. Secondary end points included disease control rate (DCR), overall survival, and safety in each cohort and both cohorts combined. Results: A total of 126 patients were treated (C4, n= 81; C5, n= 45). Median age was 72 years (range 43–92), and 87.3% had received ≥6 months of enzalutamide prior to study entry. Confirmed ORR was 12.3% (95% CI 6.1–21.5%) for C4. Median duration of response in C4 was 8.1 months (range, 2.5+ to 15.2), and 5 of these patients experienced an objective response lasting ≥6 months. DCR was 53.1% (95% CI 41.7–64.3%) in C4 and 51.1% (95% CI 35.8–66.3%) in C5. Median overall survival was 17.6 months (95% CI 14.0–22.6) in C4 and 20.8 months (95% CI 14.1–28.9) in C5. Grade ≥3 treatment-related adverse events occurred in 35 patients (27.8%); 2 patients in C4 died from immune-related adverse events (myasthenic syndrome and Guillain-Barré syndrome). Conclusions: The addition of pembrolizumab to ongoing enzalutamide treatment in patients with mCRPC that progressed on enzalutamide after initial response demonstrated modest antitumor activity with a manageable safety profile. Clinical trial registry and ID: ClinicalTrials.gov, NCT02787005.

Published
2024
Full Text
View/download PDF

21. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer

Author

Matsubara, Nobuaki, Nagamori, Satsohi, Wakumoto, Yoshiaki, Uemura, Hirotsugu, Kimura, Go, Yokomizo, Akira, Kikukawa, Hiroaki, Mizokami, Atsushi, Kosaka, Takeo, Masumori, Naoya, Kawasaki, Yoshihide, Yonese, Junji, Nasu, Yasutomo, Fukasawa, Satoshi, Sugiyama, Takayuki, Kinuya, Seigo, Hosono, Makoto, Yamaguchi, Iku, Tsutsui, Hirokazu, and Uemura, Hiroji

Published
2018
Full Text
View/download PDF

22. Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study

Author

Eto, Masatoshi, primary, Takagi, Toshio, additional, Kimura, Go, additional, Fukasawa, Satoshi, additional, Tamada, Satoshi, additional, Miura, Yuji, additional, Oya, Mototsugu, additional, Sassa, Naoto, additional, Anai, Satoshi, additional, Nozawa, Masahiro, additional, Sakai, Hideki, additional, Perini, Rodolfo, additional, Yusa, Wataru, additional, Ikezawa, Hiroki, additional, Narita, Tomoyuki, additional, and Tomita, Yoshihiko, additional

Published
2022
Full Text
View/download PDF

28. Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study.

Author

Eto, Masatoshi, Takagi, Toshio, Kimura, Go, Fukasawa, Satoshi, Tamada, Satoshi, Miura, Yuji, Oya, Mototsugu, Sassa, Naoto, Anai, Satoshi, Nozawa, Masahiro, Sakai, Hideki, Perini, Rodolfo, Yusa, Wataru, Ikezawa, Hiroki, Narita, Tomoyuki, and Tomita, Yoshihiko

Subjects
RENAL cell carcinoma, JAPANESE people, SUNITINIB, PEMBROLIZUMAB, OVERALL survival
Abstract

Background: The phase 3 CLEAR study demonstrated statistically significantly improved efficacy with lenvatinib plus pembrolizumab versus sunitinib, including progression‐free survival and overall survival, in patients with previously untreated advanced renal cell carcinoma. This subset analysis investigated efficacy and safety in Japanese patients randomized to lenvatinib plus pembrolizumab or sunitinib in the CLEAR study. Methods: Progression‐free survival, overall survival, tumor response, and safety were assessed in Japanese patients with previously untreated advanced renal cell carcinoma randomized to receive lenvatinib plus pembrolizumab (n = 42) or sunitinib (n = 31). Efficacy outcomes were analyzed by independent imaging review per Response Evaluation Criteria in Solid Tumors, version 1.1. Results: Progression‐free survival was longer with lenvatinib plus pembrolizumab than with sunitinib (median, 22.1 vs. 10.9 months; hazard ratio, 0.39; 95% CI, 0.20–0.74). Median overall survival was not estimable in the lenvatinib plus pembrolizumab arm and 30.6 months in the sunitinib arm (HR, 1.20; 95% CI, 0.39–3.66). Overall survival adjusted for the imbalance of Memorial Sloan‐Kettering Cancer Center prognostic risk group favored lenvatinib plus pembrolizumab (hazard ratio, 0.67; 95% CI, 0.18–2.39). Objective response rate (69.0% vs. 45.2%; odds ratio, 2.71; 95% CI, 1.03–7.10) was higher and median duration of response (20.3 vs. 9.1 months) was longer with lenvatinib plus pembrolizumab versus sunitinib. Grade ≥ 3 treatment‐emergent adverse events occurred in 95.2% versus 87.1% of patients in the lenvatinib plus pembrolizumab versus sunitinib arms. Conclusions: These findings support lenvatinib plus pembrolizumab as a potential first‐line treatment for Japanese patients with advanced renal cell carcinoma. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

31. Erratum to: Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma

Author

Tomita, Yoshihiko, primary, Kimura, Go, additional, Fukasawa, Satoshi, additional, Numakura, Kazuyuki, additional, Sugiyama, Yutaka, additional, Yamana, Kazutoshi, additional, Naito, Sei, additional, Kaneko, Hirokazu, additional, Tajima, Yohei, additional, and Oya, Mototsugu, additional

Published
2021
Full Text
View/download PDF

32. Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma

Author

Tomita, Yoshihiko, primary, Kimura, Go, additional, Fukasawa, Satoshi, additional, Numakura, Kazuyuki, additional, Sugiyama, Yutaka, additional, Yamana, Kazutoshi, additional, Naito, Sei, additional, Kaneko, Hirokazu, additional, Tajima, Yohei, additional, and Oya, Mototsugu, additional

Published
2021
Full Text
View/download PDF

33. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Author

Powles, Thomas, primary, Csőszi, Tibor, additional, Özgüroğlu, Mustafa, additional, Matsubara, Nobuaki, additional, Géczi, Lajos, additional, Cheng, Susanna Y-S, additional, Fradet, Yves, additional, Oudard, Stephane, additional, Vulsteke, Christof, additional, Morales Barrera, Rafael, additional, Fléchon, Aude, additional, Gunduz, Seyda, additional, Loriot, Yohann, additional, Rodriguez-Vida, Alejo, additional, Mamtani, Ronac, additional, Yu, Evan Y, additional, Nam, Kijoeng, additional, Imai, Kentaro, additional, Homet Moreno, Blanca, additional, Alva, Ajjai, additional, Cascallar, Diana Vera, additional, Varela, Mirta, additional, Lazzaro, Mauricio Fernandez, additional, Kaen, Diego Lucas, additional, Gatica, Gabriela, additional, Flores, David Hugo, additional, Falco, Agustin, additional, Molina, Matias, additional, Van Aelst, Filip, additional, Sautois, Brieuc, additional, Machiels, Jean-Pascal, additional, Schallier, Denis, additional, Brust, Leandro, additional, Rapatoni, Liane, additional, Azevedo, Sergio J, additional, Marinho, Gisele, additional, Soares, Joao Paulo Holanda, additional, Dzik, Carlos, additional, Almeida Silva, Jamile, additional, Fay, Andre Poisl, additional, Gingerich, Joel, additional, Ferrario, Cristiano, additional, Potvin, Kylea, additional, Vanhuyse, Marie, additional, Abdelsalam, Mahmoud, additional, Cheng, Susanna, additional, Caglevic, Christian, additional, Reyes, Felipe, additional, Leal, Jose Luis, additional, Francisco, Francisco, additional, Ibanez, Carolina, additional, Joly, Florence, additional, Laguerre, Brigitte, additional, Ladoire, Sylvain, additional, Flechon, Aude, additional, Topart, Delphine, additional, Huillard, Olivier, additional, Oudard, Stéphane, additional, Gross-Goupil, Marine, additional, Culine, Stephane, additional, Gravis, Gwenaelle, additional, Reichardt, Peter, additional, Retz, Margitta, additional, Herden, Jan, additional, Pfister, David, additional, Ohlman, Carsten, additional, Stoeckle, Michael, additional, Wirth, Manfred, additional, Lorch, Anja, additional, Niegisch, Guenter, additional, Goebell, Peter J, additional, Boegemann, Martin, additional, Merseburger, Axel, additional, Gakis, Georgios, additional, Bedke, Jens, additional, Neisius, Andreas, additional, Thomas, Christian, additional, Hoefner, Thomas, additional, Telekes, Andras, additional, Kosa, Judit Erzsebet, additional, Revesz, Janos, additional, Bodoky, Gyorgy, additional, Csoszi, Tibor, additional, Csejtei, Andras, additional, Geczi, Lajos, additional, Ruzsa, Agnes, additional, Kolonics, Zsuzsanna, additional, Erfan, Jozsef, additional, McDermott, Ray, additional, Bambury, Richard, additional, Sella, Avishay, additional, Frank, Stephen Jay, additional, Kejzman, Daniel, additional, Goldman, Olesya, additional, Rosenbaum, Eli, additional, Peer, Avivit, additional, Berger, Raanan, additional, Rouvinov, Keren, additional, Sarid, David, additional, Fukasawa, Satoshi, additional, Arai, Gaku, additional, Yamaguchi, Akito, additional, Yokomizo, Akira, additional, Takayama, Tatsuya, additional, Kinoshita, Hidefumi, additional, Kikuchi, Eiji, additional, Mizuno, Ryuichi, additional, Fujii, Yasuhisa, additional, Sassa, Naoto, additional, Matsukawa, Yoshihisa, additional, Fujimoto, Kiyohide, additional, Tanikawa, Toshiki, additional, Tomita, Yoshihiko, additional, Nishimura, Kazuo, additional, Tsujihata, Masao, additional, Oyama, Masafumi, additional, Masumori, Naoya, additional, Kanayama, Hiroomi, additional, Takano, Toshimi, additional, Miura, Yuji, additional, Miyazaki, Jun, additional, Joraku, Akira, additional, Kimura, Tomokazu, additional, Yamamoto, Yoshiaki, additional, Kobayashi, Kazuki, additional, De Wit, Ronald, additional, Aarts, Maureen, additional, Gerritsen, Winald, additional, Los, Maartje, additional, Beerepoot, Laurens, additional, Izmailov, Adel, additional, Gorelov, Sergey Igorevich, additional, Alekseev, Boris Yakovlevich, additional, Semenov, Andrey, additional, Kostorov, Vladimir Anatolyevich, additional, Alekseev, Sergey M, additional, Zyryanov, Alexander, additional, Oschepkov, Vasiliy Nikolaevich, additional, Shidin, Vladimir Aleksandrovich, additional, Vladimirov, Vladimir Ivanovich, additional, Gafanov, Rustem Airatovich, additional, Karlov, Petr Alexandrovich, additional, Anderson, David Brian, additional, Shepherd, Lucinda, additional, Cohen, Graham Lawrence, additional, Rapoport, Bernardo Louis, additional, Ruff, Paul, additional, Lee, Nari, additional, Bae, Woo Kyun, additional, Lee, Hyo Jin, additional, Herranz, Urbano Anido, additional, Grande, Enrique, additional, Alonso Gordoa, Teresa, additional, Guma Padro, Josep, additional, Gauna, Daniel Castellano, additional, Arranz, Jose Angel, additional, Munoz Langa, Jose, additional, Sarrio, Regina Girones, additional, Montesa Pino, Alvaro, additional, Juan Fita, Maria Jose, additional, Su, Yu-Li, additional, Lin, Yung-Chang, additional, Su, Wen-Pin, additional, Shen, Ying-Chun, additional, Chang, Yen-Hwa, additional, Huang, Yi-Hsiu, additional, Sriuranpong, Virote, additional, Chansriwong, Phichai, additional, Srimuninnimit, Vichien, additional, Danchaivijitr, Pongwut, additional, Abali, Huseyin, additional, Yavuz, Sinan, additional, Ozyilkan, Ozgur, additional, Sendur, Mehmet Ali Nahit, additional, Ekenel, Meltem, additional, Ozguroglu, Mustafa, additional, Arslan, Cagatay, additional, Ozdogan, Mustafa, additional, Birtle, Alison, additional, Powles, Thomas, additional, Huddart, Robert, additional, de Santis, Maria, additional, Zarkar, Anjali, additional, Evans, Linda, additional, Hussain, Syed, additional, DiSimone, Christopher, additional, Muina, Antonio F, additional, Schlegel, Peter, additional, Jhangiani, Haresh S, additional, Harrison, Michael, additional, Slater, Dennis E, additional, Wright, David, additional, Percent, Ivor J, additional, Lin, Jianqing, additional, Hwang, Clara, additional, Gupta, Sumati, additional, Bajaj, Madhuri, additional, Galamaga, Robert, additional, Eklund, John, additional, Wallace, James, additional, Shtivelband, Mikhail, additional, Suh, Jason Jung-Gon, additional, Burhani, Nafisa, additional, Eadens, Matthew, additional, Gunturu, Krishna, additional, Burgess, Earle, additional, Wong, John, additional, Chaudhry, Arvind, additional, Van Veldhuizen, Peter, additional, Graff, Stephanie, additional, Thomas, Christian A, additional, Schnadig, Ian D, additional, Carneiro, Benedito, additional, Hussain, Maha, additional, Morgans, Alicia, additional, Fitzharris, John T, additional, Oliff, Ira A, additional, Vuky, Jacqueline, additional, Hauke, Ralph, additional, Baron, Ari, additional, Joshi, Monika, additional, Bolemon, Britt H, additional, Jiang, Peter, additional, Mega, Anthony E, additional, Markus, Maurice, additional, Pfanzelter, Nicklas, additional, Lawler, William Eyre, additional, Cobb, Patrick Wayne, additional, Courtright, Jay G, additional, Jain, Sharad, additional, Doshi, Gurjyot, additional, Gunuganti, Vijay K, additional, Sartor, Oliver Alton, additional, Cole, Scott W, additional, Babiker, Hani, additional, Uchio, Edward M, additional, Drakaki, Alexandra, additional, Mannuel, Heather D, additional, Guancial, Elizabeth, additional, Fung, Chunkit, additional, Charles, Anthony, additional, Amato, Robert J, additional, Arriaga, Yull, additional, Bowman, Isaac, additional, Ades, Steven, additional, Dreicer, Robert, additional, Yu, Evan, additional, Quinn, David I, additional, and Fleming, Mark, additional

Published
2021
Full Text
View/download PDF

34. Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients : a subgroup analysis of the phase 3 KEYNOTE-045 trial

Author

Nishiyama, Hiroyuki, Yamamoto, Yoshiaki, Sassa, Naoto, Nishimura, Kazuo, Fujimoto, Kiyohide, Fukasawa, Satoshi, Yokoyama, Minato, Enokida, Hideki, Takahashi, Kenichi, Tanaka, Yoshinobu, Imai, Kentaro, Shimamoto, Takashi, Perini, Rodolfo, Frenkl, Tara, Bajorin, Dean F., and Bellmunt Molins, Joaquim, 1959

Subjects
Male, 0301 basic medicine, Oncology, medicine.medical_treatment, Docetaxel, Pembrolizumab, chemistry.chemical_compound, 0302 clinical medicine, Japan, Antineoplastic Combined Chemotherapy Protocols, Aged, 80 and over, education.field_of_study, Vinflunine, Hematology, General Medicine, Middle Aged, Survival Rate, Treatment Outcome, 030220 oncology & carcinogenesis, Original Article, Female, medicine.drug, Urologic Neoplasms, medicine.medical_specialty, KEYNOTE-045, Paclitaxel, Population, Antibodies, Monoclonal, Humanized, Vinblastine, Lower risk, 03 medical and health sciences, Internal medicine, medicine, Humans, education, Survival rate, Aged, Carcinoma, Transitional Cell, Chemotherapy, Bladder cancer, Advanced urothelial cancer, business.industry, medicine.disease, 030104 developmental biology, Urinary Bladder Neoplasms, chemistry, Japanese, Surgery, Neoplasm Recurrence, Local, business, Immune checkpoint blockade
Abstract

Background The open-label, randomized, active-controlled KEYNOTE-045 study (NCT02256436) showed that second-line pembrolizumab significantly improved overall survival (OS) of patients with advanced/metastatic urothelial cancer (UC) that progressed after first-line platinum-containing chemotherapy, compared with standard chemotherapy (paclitaxel, docetaxel, or vinflunine). Pembrolizumab is approved for patients with bladder cancer in Japan. Patients and methods Analysis was performed in the subgroup of Japanese patients enrolled in the KEYNOTE-045 study. Coprimary end points were OS and progression-free survival (PFS). Objective response rate (ORR) and safety were secondary end points. Results Fifty-two Japanese patients (pembrolizumab, n = 30; chemotherapy, n = 22) were followed up for a median of 26.1 months. Patients who received pembrolizumab compared with chemotherapy had a 19% lower risk for death (hazard ratio [HR] 0.81, 95% CI 0.44–1.50); after adjusting for baseline covariates, the HR for OS was 0.61 (95% CI 0.32–1.15). The 24-month OS rate was higher with pembrolizumab (26.9% vs 14.3%). PFS was 2.0 and 4.9 months for pembrolizumab and chemotherapy, respectively (HR 1.71, 95% CI 0.95–3.08). ORR was similar for pembrolizumab and chemotherapy (20.0% vs 18.2%); durability of response was higher with pembrolizumab: 67% and 33% of patients, respectively, maintained a response for > 12 months. Treatment-related adverse events, including grade 3–5 events, occurred less frequently with pembrolizumab. Conclusions Pembrolizumab provided durable antitumor activity in patients with locally advanced/metastatic UC that progressed after platinum-containing chemotherapy in the overall population and in the Japanese subgroup; safety profile was consistent with that previously observed for pembrolizumab.

Published
2019

37. Phase I/II study to evaluate the efficacy of TAS0313, a cancer peptide vaccine, combined with pembrolizumab for locally advanced or metastatic urothelial carcinoma.

Author

Matsumoto, Ryuji, primary, Yonese, Junji, additional, Kawahara, Takashi, additional, Miyake, Hideaki, additional, Matsubara, Nobuaki, additional, Uemura, Hiroji, additional, Eto, Masatoshi, additional, Azuma, Haruhito, additional, Obara, Wataru, additional, Terai, Akito, additional, Fukasawa, Satoshi, additional, Suekane, Shigetaka, additional, and Nishiyama, Hiroyuki, additional

Published
2021
Full Text
View/download PDF

38. Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone‐sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study

Author

Iguchi, Taro, primary, Kimura, Go, additional, Fukasawa, Satoshi, additional, Suzuki, Hiroyoshi, additional, Uemura, Hiroji, additional, Nishimura, Kazuo, additional, Matsumoto, Hiroaki, additional, Yokomizo, Akira, additional, Armstrong, Andrew J, additional, Rosbrook, Brad, additional, Sugg, Jennifer, additional, Baron, Benoit, additional, Chen, Lucy, additional, Kunieda, Futoshi, additional, and Stenzl, Arnulf, additional

Published
2021
Full Text
View/download PDF

41. Efficacy and safety of subsequent molecular targeted therapy after immuno-checkpoint therapy, retrospective study of Japanese patients with metastatic renal cell carcinoma (AFTER I-O study)

Author

Tomita, Yoshihiko, primary, Kimura, Go, additional, Fukasawa, Satoshi, additional, Numakura, Kazuyuki, additional, Sugiyama, Yutaka, additional, Yamana, Kazutoshi, additional, Naito, Sei, additional, Kabu, Koki, additional, Tajima, Yohei, additional, and Oya, Mototsugu, additional

Published
2021
Full Text
View/download PDF

43. Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial

Author

Uemura, Hiroji, primary, Matsushima, Hisashi, additional, Kobayashi, Kazuki, additional, Mizusawa, Hiroya, additional, Nishimatsu, Hiroaki, additional, Fizazi, Karim, additional, Smith, Matthew, additional, Shore, Neal, additional, Tammela, Teuvo, additional, Tabata, Ken-ichi, additional, Matsubara, Nobuaki, additional, Iinuma, Masahiro, additional, Uemura, Hirotsugu, additional, Oya, Mototsugu, additional, Momma, Tetsuo, additional, Kawakita, Mutsushi, additional, Fukasawa, Satoshi, additional, Kobayashi, Tadahiro, additional, Kuss, Iris, additional, Le Berre, Marie-Aude, additional, Snapir, Amir, additional, Sarapohja, Toni, additional, and Suzuki, Kazuhiro, additional

Published
2020
Full Text
View/download PDF

44. A randomized phase III trial of personalized peptide vaccination for castration‑resistant prostate cancer progressing after docetaxel

Author

Noguchi, Masanori, primary, Fujimoto, Kiyohide, additional, Arai, Gaku, additional, Uemura, Hiroji, additional, Hashine, Katsuyoshi, additional, Matsumoto, Hiroaki, additional, Fukasawa, Satoshi, additional, Kohjimoto, Yasuo, additional, Nakatsu, Hideomi, additional, Takenaka, Atsushi, additional, Fujisawa, Masato, additional, Uemura, Hirotsugu, additional, Naito, Seiji, additional, Egawa, Shin, additional, Fujimoto, Hiroyuki, additional, Hinotsu, Shiro, additional, and Itoh, Kyogo, additional

Published
2020
Full Text
View/download PDF

48. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial

Author

Motzer, Robert J., primary, Escudier, Bernard, additional, George, Saby, additional, Hammers, Hans J., additional, Srinivas, Sandhya, additional, Tykodi, Scott S., additional, Sosman, Jeffrey A., additional, Plimack, Elizabeth R., additional, Procopio, Giuseppe, additional, McDermott, David F., additional, Castellano, Daniel, additional, Choueiri, Toni K., additional, Donskov, Frede, additional, Gurney, Howard, additional, Oudard, Stéphane, additional, Richardet, Martin, additional, Peltola, Katriina, additional, Alva, Ajjai S., additional, Carducci, Michael, additional, Wagstaff, John, additional, Chevreau, Christine, additional, Fukasawa, Satoshi, additional, Tomita, Yoshihiko, additional, Gauler, Thomas C., additional, Kollmannsberger, Christian K., additional, Schutz, Fabio A., additional, Larkin, James, additional, Cella, David, additional, McHenry, M. Brent, additional, Saggi, Shruti Shally, additional, and Tannir, Nizar M., additional

Published
2020
Full Text
View/download PDF

49. Prognostic factors influencing overall survival in de novo oligometastatic prostate cancer patients

Author

Rii, Junryo, primary, Sakamoto, Shinichi, additional, Yamada, Yasutaka, additional, Takeshita, Nobushige, additional, Yamamoto, Satoshi, additional, Sazuka, Tomokazu, additional, Imamura, Yusuke, additional, Nakamura, Kazuyoshi, additional, Komiya, Akira, additional, Komaru, Atsushi, additional, Fukasawa, Satoshi, additional, Nakatsu, Hiroomi, additional, Akakura, Koichiro, additional, and Ichikawa, Tomohiko, additional

Published
2020
Full Text
View/download PDF

50. Phase II study of pembrolizumab in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer (mCRPC): Updated follow-up of cohorts (C) one to three from KEYNOTE-199.

Author

Goh, Jeffrey C., primary, Piulats Rodriguez, Jose Maria M., additional, Gross-Goupil, Marine, additional, Vaishampayan, Ulka N., additional, De Wit, Ronald, additional, Alanko, Tuomo, additional, Fukasawa, Satoshi, additional, Tabata, Kenichi, additional, Feyerabend, Susan, additional, Berger, Raanan, additional, Wu, Haiyan, additional, Kim, Jeri, additional, Schloss, Charles, additional, De Bono, Johann S., additional, and Antonarakis, Emmanuel S., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results